Sugi Predict

Sugi Predict / Compounds / SCHEMBL10945

SCHEMBL10945

SCHEMBL10945

Cn1c(=O)c2c(ncn2Cc2oc3ccc(Br)cc3c(=O)c2-c2ccccc2)n(C)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ RXFP1 Q9HBX9 3/20 0.52
▸ ADORA2B P29275 3/20 0.52
▸ ALDH1A1 P00352 1/20 0.46
▸ UBE2N P61088 2/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ GLA P06280 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ TSHR P16473 1/20 0.45
▸ LMNA P02545 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ TP53 P04637 1/20 0.43
▸ ABCC8 Q09428 1/20 0.42
▸ KCNJ11 Q14654 1/20 0.42
▸ USP2 O75604 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ HIF1A Q16665 1/20 0.41
▸ PORCN Q9H237 1/20 0.41
▸ MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17970674 0.90 HTT (0.53) HTTSMN1; SMN2RXFP1ADORA2BALDH1A1
SCHEMBL10907 0.78 CYP11B1 (0.44) HTTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL29651707 0.78 CYP11B1 (0.44) HTTSMN1; SMN2ALDH1A1TSHRLMNA
SCHEMBL7930 0.76 ADORA2A (0.48) SMN1; SMN2LMNA
SCHEMBL11438 0.76 ALDH1A1 (0.38) SMN1; SMN2ALDH1A1TSHRLMNAMAPK1
SCHEMBL12852 0.76 HDAC6 (0.40) —
SCHEMBL30670814 0.76 ADORA2A (0.48) SMN1; SMN2LMNA
SCHEMBL8459 0.72 GABRP (0.51) SMN1; SMN2L3MBTL1TSHRLMNAMAPK1
SCHEMBL30694901 0.72 GABRP (0.51) SMN1; SMN2CASP1TSHRMAPK1TP53
SCHEMBL8599 0.72 GABRP (0.51) SMN1; SMN2CASP1TSHRMAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US claimed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US claimed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP claimed
US-20200239427-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2020-07-30 — — US claimed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 — — EP claimed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP claimed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO claimed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 — — US disclosed
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS CURON BIOPHARMACEUTICAL (SHANGHAI) CO., LIMITED (CN) 2024-05-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 — — US disclosed
EP-4292596-A1 METHOD AND COMBINATION FOR TREATING TUMORS Curon Biopharmaceutical (Shanghai) Co., Limited (CN) 2023-12-20 — — EP disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885SMN1; SMN2 2637/4885RXFP1 4015/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885SMN1; SMN2 2637/4885RXFP1 4015/4885
US-20200239427-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885SMN1; SMN2 2637/4885RXFP1 4015/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A HTT 3291/4885SMN1; SMN2 2484/4885RXFP1 1552/4885
US-20240139198-A1 METHOD AND COMBINATION FOR TREATING TUMORS PDCD1, PDCD1LG2, CD274 HTT 4666/4885SMN1; SMN2 4576/4885RXFP1 2610/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB HTT 3125/4885SMN1; SMN2 2637/4885RXFP1 4015/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.